Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center.

recurrence resection margin distance survival vulvar cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Aug 2023
Historique:
received: 20 07 2023
revised: 11 08 2023
accepted: 14 08 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

The aim of this study was to evaluate the impact of pathological tumor-free margin distance on survival in SCC patients treated with surgery alone. This retrospective study included 128 patients with node-negative disease that received no adjuvant treatment. Disease-free and overall survival were analyzed according to pathological tumor-free margin distance. The patients were subclassified into three resection margin category groups: "1 to 3 mm" (n = 42), ">3 to 8 mm" (n = 47) or ">8 mm" (n = 39). Thirty-nine of the 128 patients (30.5%) developed recurrent disease. Median follow-up for disease-free survival (DFS) was 6.49 years (95% CI 5.16 years; 7.62 years), and median follow-up for overall survival (OS) was 6.29 years (95% CI 5.45 years; 7.33 years). The 5-year DFS rate was 0.70 (95% CI: 0.62-0.79), and the 5-year OS rate was 0.79 (95% CI: 0.71-0.87). Regarding the survival outcome, there were no independent significant differences in either disease-free survival (DFS) ( The present study did not show a significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva (that did not receive adjuvant treatment) on disease-free and overall survival.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to evaluate the impact of pathological tumor-free margin distance on survival in SCC patients treated with surgery alone.
METHODS METHODS
This retrospective study included 128 patients with node-negative disease that received no adjuvant treatment. Disease-free and overall survival were analyzed according to pathological tumor-free margin distance.
RESULTS RESULTS
The patients were subclassified into three resection margin category groups: "1 to 3 mm" (n = 42), ">3 to 8 mm" (n = 47) or ">8 mm" (n = 39). Thirty-nine of the 128 patients (30.5%) developed recurrent disease. Median follow-up for disease-free survival (DFS) was 6.49 years (95% CI 5.16 years; 7.62 years), and median follow-up for overall survival (OS) was 6.29 years (95% CI 5.45 years; 7.33 years). The 5-year DFS rate was 0.70 (95% CI: 0.62-0.79), and the 5-year OS rate was 0.79 (95% CI: 0.71-0.87). Regarding the survival outcome, there were no independent significant differences in either disease-free survival (DFS) (
CONCLUSION CONCLUSIONS
The present study did not show a significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva (that did not receive adjuvant treatment) on disease-free and overall survival.

Identifiants

pubmed: 37627138
pii: cancers15164110
doi: 10.3390/cancers15164110
pmc: PMC10452494
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Surg Oncol. 2015 Dec;41(12):1653-8
pubmed: 26507171
Cancers (Basel). 2022 Aug 29;14(17):
pubmed: 36077719
Acta Obstet Gynecol Scand. 2021 Aug;100(8):1520-1525
pubmed: 33811323
Int J Gynecol Cancer. 2022 Mar;32(3):332-337
pubmed: 35256420
Cancers (Basel). 2023 Jan 06;15(2):
pubmed: 36672338
J Cancer Res Clin Oncol. 2016 Feb;142(2):489-95
pubmed: 26498775
Eur J Cancer. 2016 Dec;69:180-188
pubmed: 27837710
Cancers (Basel). 2020 Nov 14;12(11):
pubmed: 33202675
Gynecol Oncol. 2013 Sep;130(3):545-9
pubmed: 23747330
Ann Surg Oncol. 2011 Dec;18(13):3811-8
pubmed: 21594705
Eur J Surg Oncol. 2019 Nov;45(11):2109-2114
pubmed: 31285094
Int J Gynecol Cancer. 2023 Jul 3;33(7):1023-1043
pubmed: 37369376
J Gynecol Oncol. 2016 Nov;27(6):e60
pubmed: 27550406
Minerva Obstet Gynecol. 2021 Apr;73(2):160-165
pubmed: 33306289
Arch Gynecol Obstet. 2022 Jan;305(1):233-240
pubmed: 34387725
Prev Med. 2022 Nov;164:107302
pubmed: 36240909
Eur J Cancer. 2016 Sep;65:139-49
pubmed: 27497345
Obstet Gynecol. 1983 Jan;61(1):63-74
pubmed: 6823350
J Obstet Gynaecol Res. 2021 Nov;47(11):3990-3997
pubmed: 34365709
Arch Gynecol Obstet. 2023 Jun;307(6):1677-1686
pubmed: 35608701
Gynecol Oncol. 1998 Oct;71(1):116-21
pubmed: 9784331
Gynecol Oncol. 2007 Mar;104(3):636-41
pubmed: 17095080

Auteurs

Florin Andrei Taran (FA)

Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.

Jana Pasternak (J)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Annette Staebler (A)

Institute of Pathology and Neuropathology, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Annika Rohner (A)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Felix Neis (F)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Tobias Engler (T)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Ernst Oberlechner (E)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Birgitt Schönfisch (B)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Ingolf Juhasz-Böss (I)

Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.

Andreas Daniel Hartkopf (AD)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Sara Brucker (S)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Christina Barbara Walter (CB)

Department of Women's Health, Tuebingen University Hospital, 72076 Tuebingen, Germany.

Classifications MeSH